Clinical Trial Update: Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema [Phase 1]

View source ↗

Summary

This clinical trial entry reports that PRO-169 is being evaluated in Phase 1 for safety and immunogenicity in diabetic macular edema, with the study currently n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• PRO-169

Snippet

Sponsor: Laboratorios Sophia S.A de C.V. | Conditions: Immunogenicity, Anti-drug Antibodies (ADAs) | Phase 1 | Status: NOT_YET_RECRUITING